Close

move up move left move right move bottom

The #1 prescribed novel oral anticoagulant in the US*1

DVT and PE Treatment and Risk Reduction

Proven efficacy and safety profile versus the standard of care (enoxaparin + warfarin)

 

Indications

 

IMPORTANT SAFETY INFORMATION

 

Indication and Important saftey Information

 

INDICATIONS

  • Reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF). There are limited data on the relative effectiveness of XARELTO® (rivaroxaban) and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well controlled.
  • Treatment of deep vein thrombosis (DVT).
  • Treatment of pulmonary embolism (PE).
  • Reduction in the risk of recurrence of DVT and of PE following initial 6 months treatment for DVT and/or PE.
  • Prophylaxis of DVT, which may lead to PE in patients undergoing knee replacement surgery.
  • Prophylaxis of DVT, which may lead to PE in patients undergoing hip replacement surgery.

References:

  1. Data on file. Janssen Pharmaceuticals, Inc. Based on IMS Health, NPA Weekly, April 2015.
  2. Prins MH, Lensing AWA, Bauersachs R, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013;11(1):21. doi:10.1186/1477-9560-11-21.